On December 4, 2024, shares of Lincoln Pharmaceuticals surged 20% to ₹904.90, marking a lifetime high and reaching the upper circuit limit in intraday trading on the Bombay Stock Exchange (BSE). The small-cap stock opened at ₹782.90, up from the previous close of ₹754.10, and continued its remarkable rise. This surge represents an impressive 38% gain over just three trading sessions in December, continuing its strong momentum.

Debt-Free Status and Strong Financial Performance
One of the key highlights of Lincoln Pharma is its debt-free status. As of September 2024, the company reported a net profit exceeding ₹100 crore annually and a robust investment portfolio of over ₹164 crore, with healthy return ratios. For the first half of FY25 (H1FY25), Lincoln Pharma posted a standalone net profit of ₹50.03 crore, reflecting a year-on-year (YoY) growth of 7.55%, compared to ₹46.52 crore in H1FY24. Its income from operations for the period stood at ₹308.50 crore, a 5.79% YoY increase, while the EBITDA reached ₹71.50 crore, up by 4.76% YoY.

Strategic Growth and Expansion Plans
Commenting on the company’s results, Mahendra Patel, Managing Director of Lincoln Pharmaceuticals, expressed satisfaction with the continued strong growth across all business verticals. Patel attributed the company’s growth to new product launches in both domestic and export markets, strengthening its market presence. These initiatives, combined with robust growth strategies and operational improvements, have positioned Lincoln Pharma for an even stronger second half of FY25.

The company’s goal of achieving ₹750 crore in revenue by FY26 is within reach, as it continues to make significant strides in geographic expansion and product development. Patel highlighted that Lincoln Pharma is among the few companies that have achieved consistent profit growth every year from FY13 to FY24.

Global Expansion and Market Penetration
Lincoln Pharma's global expansion efforts are gaining momentum, with exports reaching over 60 countries. The company recently entered the Canadian market and secured approvals from the Therapeutic Goods Administration (TGA) in Australia and EU GMP certification, further positioning it for global growth. Additionally, Lincoln Pharma is pursuing product registration for its Cephalosporin plant in Mehsana, India, as part of its plan to expand its product offerings and market presence globally.

Stock Performance and Trends
At ₹904.90, Lincoln Pharma’s share price has surged 82% from its 52-week low of ₹498, recorded on June 5, 2024. The stock has gained about 49% in the current year alone, indicating strong investor confidence in its growth trajectory. As the company continues to expand globally and achieve consistent financial performance, Lincoln Pharma remains an attractive prospect for investors, especially considering its debt-free status and strategic growth initiatives.